Genotype Correlations with Blood Pressure and Efficacy from a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer

Volumn 13, Issue 4, 2015, Pages 328-337.e3

  Escudier, Bernard ^a   Rini, Brian I ^b   Motzer, Robert J ^c   Tarazi, Jamal ^d   Kim, Sinil ^d   Huang, Xin ^d   Rosbrook, Brad ^d   English, Patricia A ^d   Loomis, A Katrina ^d   Williams, J Andrew ^d  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d PFIZER INC   (United States)

Author keywords

Angiogenesis; Biomarker; Interpatient; Pharmacogenomic; Single nucleotide polymorphism

Indexed keywords

AXITINIB; DNA; HYPOXIA INDUCIBLE FACTOR 1ALPHA; SORAFENIB; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; CARBANILAMIDE DERIVATIVE; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; NICOTINAMIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2, HUMAN;

AGED; ALLELE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATIONAL STUDY; DIASTOLIC BLOOD PRESSURE; EXPLORATORY RESEARCH; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC LINKAGE; GENOTYPE; HARDY WEINBERG EQUILIBRIUM; HUMAN; HYPERTENSION; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OPEN STUDY; OUTCOME ASSESSMENT; PHARMACOGENOMICS; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE; ANALOGS AND DERIVATIVES; BLOOD PRESSURE; CARCINOMA, RENAL CELL; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG EFFECTS; GENETICS; KAPLAN MEIER METHOD; KIDNEY NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL;

AGED; ANGIOGENESIS INHIBITORS; BLOOD PRESSURE; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; IMIDAZOLES; INDAZOLES; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NIACINAMIDE; PHENYLUREA COMPOUNDS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84928615600     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2015.02.007     Document Type: Article

References (45)

1. J. Folkman Tumor angiogenesis: therapeutic implications N Engl J Med 285 1971 1182 1186
2. T. Funakoshi, C.H. Lee, and J.J. Hsieh A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma Cancer Treat Rev 40 2014 533 547
3. J. Garcia-Donas, C. Rodriguez-Antona, and E. Jonasch Molecular markers to predict response to therapy Semin Oncol 40 2013 444 458
4. B.P. Schneider, F. Shen, and K.D. Miller Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment Lancet Oncol 13 2012 e427 e436
5. L. Eng, A.K. Azad, and S. Habbous Vascular endothelial growth factor pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a systematic review and meta-analysis Clin Cancer Res 18 2012 4526 4537
6. L. Eng, and G. Liu VEGF pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a 2013 update Pharmacogenomics 14 2013 1659 1667
7. D. Lambrechts, B. Claes, and P. Delmar VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials Lancet Oncol 13 2012 724 733
8. K. Eechoute, A.A. van der Veldt, and S. Oosting Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension Clin Pharmacol Ther 92 2012 503 510
9. N.P. van Erp, K. Eechoute, and A.A. van der Veldt Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity J Clin Oncol 27 2009 4406 4412
10. M. Scartozzi, M. Bianconi, and L. Faloppi VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib Br J Cancer 108 2013 1126 1132
11. B. Beuselinck, A. Karadimou, and D. Lambrechts Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib Br J Cancer 108 2013 887 900
12. B. Beuselinck, A. Karadimou, and D. Lambrechts VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis Acta Oncol 53 2014 103 112
13. J. Garcia-Donas, E. Esteban, and L.J. Leandro-Garcia Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study Lancet Oncol 12 2011 1143 1150
14. J.J. Kim, S.A. Vaziri, and B.I. Rini Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib Cancer 118 2012 1946 1954
15. A.A. van der Veldt, K. Eechoute, and H. Gelderblom Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib Clin Cancer Res 17 2011 620 629
16. H.R. Kim, H.S. Park, and W.S. Kwon Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients Cancer Chemother Pharmacol 72 2013 825 835
17. C.F. Xu, N.X. Bing, and H.A. Ball Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes J Clin Oncol 29 2011 2557 2564
18. D.D. Hu-Lowe, H.Y. Zou, and M.L. Grazzini Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3 Clin Cancer Res 14 2008 7272 7283
19. B.I. Rini, G. Wilding, and G. Hudes Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma J Clin Oncol 27 2009 4462 4468
20. O. Rixe, R.M. Bukowski, and M.D. Michaelson Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study Lancet Oncol 8 2007 975 984
21. B.I. Rini, B. Escudier, and P. Tomczak Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Lancet 378 2011 1931 1939
22. J.H. Schiller, T. Larson, and S.H. Ou Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study J Clin Oncol 27 2009 3836 3841
23. J. Fruehauf, J. Lutzky, and D. McDermott Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma Clin Cancer Res 17 2011 7462 7469
24. Y. Tomita, H. Uemura, and H. Fujimoto Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma Eur J Cancer 47 2011 2592 2602
25. E.E. Cohen, L.S. Rosen, and E.E. Vokes Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study J Clin Oncol 26 2008 4708 4713
26. T.E. Hutson, V. Lesovoy, and S. Al-Shukri Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial Lancet Oncol 14 2013 1287 1294
27. R.J. Motzer, B. Escudier, and P. Tomczak Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial Lancet Oncol 14 2013 552 562
28. B.I. Rini, B. Melichar, and T. Ueda Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial Lancet Oncol 14 2013 1233 1242
29. L.D. Locati, L. Licitra, and L. Agate Treatment of advanced thyroid cancer with axitinib: phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments Cancer 120 2014 2694 2703
30. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
31. B.P. Schneider, M. Wang, and M. Radovich Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100 J Clin Oncol 26 2008 4672 4678
32. J.G. Kim, Y.S. Chae, and S.K. Sohn Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer Clin Cancer Res 14 2008 62 66
33. M.I. Koukourakis, D. Papazoglou, and A. Giatromanolaki VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer Lung Cancer 46 2004 293 298
34. R.S. Heist, R. Zhai, and G. Liu VEGF polymorphisms and survival in early-stage non-small-cell lung cancer J Clin Oncol 26 2008 856 862
35. P. Krippl, U. Langsenlehner, and W. Renner A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk Int J Cancer 106 2003 468 471
36. D. Menendez, O. Krysiak, and A. Inga A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network Proc Natl Acad Sci U S A 103 2006 1406 1411
37. Y. Wang, Y. Zheng, and W. Zhang Polymorphisms of KDR gene are associated with coronary heart disease J Am Coll Cardiol 50 2007 760 767
38. J. Nadaoka, Y. Horikawa, and M. Saito Prognostic significance of HIF-1 alpha polymorphisms in transitional cell carcinoma of the bladder Int J Cancer 122 2008 1297 1302
39. K.J. Livak, S.J. Flood, and J. Marmaro Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization PCR Methods Appl 4 1995 357 362
40. J.M. Bland, and D.G. Altman Multiple significance tests: the Bonferroni method BMJ 310 1995 170
41. K. Tanimoto, K. Yoshiga, and H. Eguchi Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance Carcinogenesis 24 2003 1779 1783
42. B. Paule, L. Bastien, and E. Deslandes Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas PLoS One 5 2010 e10715
43. J. Garcia-Donas, L.J. Leandro-Garcia, and A. Gonzalez Del Alba Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma Ann Oncol 24 2013 2409 2414
44. B. Escudier, and M. Gore Axitinib for the management of metastatic renal cell carcinoma Drugs R D 11 2011 113 126
45. M. Scartozzi, L. Faloppi, and G. Svegliati Baroni VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study Int J Cancer 135 2014 1247 1256